X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pyrazines - pharmacology (4618) 4618
science & technology (3919) 3919
life sciences & biomedicine (3744) 3744
humans (3591) 3591
animals (3332) 3332
male (2131) 2131
bortezomib (1900) 1900
boronic acids - pharmacology (1477) 1477
pharmacology & pharmacy (1391) 1391
rats (1293) 1293
female (1287) 1287
mice (1142) 1142
pyrazines - therapeutic use (1093) 1093
oncology (1011) 1011
antineoplastic agents - pharmacology (1004) 1004
cell line, tumor (978) 978
apoptosis - drug effects (841) 841
pyrazines - chemistry (750) 750
pyrazines - administration & dosage (749) 749
dose-response relationship, drug (651) 651
middle aged (596) 596
pyrazine derivatives (587) 587
apoptosis (583) 583
pharmacology, medicinal chemistry, vaccines, serums (568) 568
pyrazines - chemical synthesis (552) 552
adult (540) 540
rats, sprague-dawley (514) 514
biochemistry & molecular biology (504) 504
structure-activity relationship (495) 495
proteasome inhibitors (483) 483
protease inhibitors - pharmacology (468) 468
boronic acids - therapeutic use (466) 466
chemistry (463) 463
multiple myeloma - drug therapy (458) 458
cell proliferation - drug effects (427) 427
aged (417) 417
hematology (395) 395
cancer (389) 389
sitagliptin phosphate (388) 388
in vitro techniques (381) 381
physical sciences (380) 380
drug synergism (376) 376
analysis (361) 361
multiple myeloma (357) 357
chemistry, medicinal (356) 356
research (356) 356
antineoplastic agents - therapeutic use (352) 352
cell biology (339) 339
amiloride - pharmacology (325) 325
pyrazines - pharmacokinetics (324) 324
boronic acids - administration & dosage (320) 320
time factors (319) 319
pyrazines - adverse effects (317) 317
cells, cultured (313) 313
abridged index medicus (303) 303
cell line (295) 295
cell survival - drug effects (293) 293
proteasome endopeptidase complex - metabolism (286) 286
disease models, animal (281) 281
molecular structure (281) 281
pyrazines (278) 278
signal transduction - drug effects (278) 278
triazoles - pharmacology (266) 266
treatment outcome (264) 264
pyrazines - metabolism (256) 256
care and treatment (240) 240
multiple myeloma - pathology (239) 239
proteins (231) 231
diabetes mellitus, type 2 - drug therapy (229) 229
nf-kappa b - metabolism (228) 228
blotting, western (227) 227
research article (227) 227
endocrinology & metabolism (225) 225
enzyme inhibitors - pharmacology (224) 224
tumor cells, cultured (223) 223
xenograft model antitumor assays (221) 221
imidazoles - pharmacology (217) 217
antineoplastic combined chemotherapy protocols - therapeutic use (212) 212
drug therapy (211) 211
health aspects (211) 211
rats, wistar (208) 208
sodium - metabolism (207) 207
tetramethylpyrazine (206) 206
pyridines - pharmacology (203) 203
kinetics (202) 202
signal transduction (200) 200
administration, oral (198) 198
neurosciences (188) 188
medicine & public health (187) 187
medicine, research & experimental (186) 186
neurosciences & neurology (186) 186
research & experimental medicine (186) 186
drug resistance, neoplasm (185) 185
mice, inbred c57bl (184) 184
multiple myeloma - metabolism (182) 182
physiological aspects (180) 180
triazoles - therapeutic use (179) 179
dogs (178) 178
protein kinase inhibitors - pharmacology (176) 176
sitagliptin (174) 174
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6650) 6650
Chinese (288) 288
Japanese (145) 145
German (58) 58
French (35) 35
Italian (33) 33
Russian (32) 32
Polish (31) 31
Spanish (10) 10
Hungarian (8) 8
Portuguese (3) 3
Czech (2) 2
Romanian (2) 2
Slovak (2) 2
Dutch (1) 1
Finnish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Cancer research (Chicago, Ill.), ISSN 0008-5472, 07/2017, Volume 77, Issue 14, pp. 3870 - 3884
Effective targeted therapies for small-cell lung cancer (SCLC), the most aggressive form of lung cancer, remain urgently needed. Here we report evidence of... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Lung Neoplasms - drug therapy | Humans | Pyrazines - administration & dosage | Small Cell Lung Carcinoma - enzymology | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Cisplatin - administration & dosage | Gene Knockdown Techniques | Biomarkers, Tumor - metabolism | Female | Pyrazoles - pharmacology | Lung Neoplasms - genetics | Phthalazines - administration & dosage | Checkpoint Kinase 1 - antagonists & inhibitors | Small Cell Lung Carcinoma - genetics | Cisplatin - pharmacology | Piperazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Drug Synergism | Checkpoint Kinase 1 - metabolism | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Pyrazoles - administration & dosage | Small Cell Lung Carcinoma - pathology | Animals | Mice, Nude | Cell Line, Tumor | Mice | Pyrazines - pharmacology | Checkpoint Kinase 1 - genetics | Medical research | Cell culture | Effectiveness | Small cell lung carcinoma | RNA-mediated interference | CHK1 protein | Lung cancer | Clinical trials | Poly(ADP-ribose) polymerase | Pharmacology | Myc protein | Kinases | Cisplatin | Anticancer properties | Amplification | Inhibitors | Platinum | Biomarkers | Antitumor activity | Inhibition | Cancer | Index Medicus
Journal Article
Cancer research (Chicago, Ill.), ISSN 1538-7445, 04/2013, Volume 73, Issue 12, pp. 3683 - 3691
Replication stress and DNA damage activate the ATR-Chk1 checkpoint signaling pathway that licenses repair and cell survival processes. In this study, we... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Protein Kinases - metabolism | Protein Kinases - genetics | Humans | Ovarian Neoplasms - pathology | Cell Survival - genetics | Deoxycytidine - pharmacology | Immunoblotting | Sulfones - pharmacology | Cell Cycle Proteins - antagonists & inhibitors | Dose-Response Relationship, Drug | Ovarian Neoplasms - genetics | RNA Interference | BRCA1 Protein - metabolism | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Cycle Proteins - genetics | Female | Antineoplastic Agents - pharmacology | Ovarian Neoplasms - metabolism | Phosphorylation - drug effects | cdc25 Phosphatases - metabolism | Protein-Serine-Threonine Kinases - metabolism | Pyrazoles - pharmacology | Cell Survival - drug effects | Topotecan - pharmacology | Cell Cycle Proteins - metabolism | Protein-Serine-Threonine Kinases - genetics | Signal Transduction - genetics | cdc25 Phosphatases - genetics | Ataxia Telangiectasia Mutated Proteins | Cisplatin - pharmacology | Pyrimidines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors | BRCA1 Protein - genetics | Poly(ADP-ribose) Polymerases - metabolism | BRCA2 Protein - metabolism | Signal Transduction - drug effects | Cell Line, Tumor | Benzimidazoles - pharmacology | Checkpoint Kinase 1 | Pyrazines - pharmacology | BRCA2 Protein - genetics | Deoxycytidine - analogs & derivatives | Index Medicus | homologous recombination | ovarian cancer | Poly(ADP-ribose) polymerase | veliparib | gemcitabine | BRCA1 | cisplatin | BRCA2 | topotecan
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 07/2013, Volume 98, Issue 7, pp. E1163 - E1172
Context: Inhibition of dipeptidyl peptidase-4 (DPP-4) is a potent strategy to increase glucose-dependent insulinotropic polypeptide and glucagon like peptide 1... 
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Palmitic Acid - metabolism | Dipeptidyl Peptidase 4 - metabolism | Antioxidants - chemistry | Dipeptidyl Peptidase 4 - chemistry | Humans | Interleukin 1 Receptor Antagonist Protein - genetics | Peptide Fragments - pharmacology | Interleukin-1beta - genetics | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Insulin-Secreting Cells - metabolism | Anti-Inflammatory Agents, Non-Steroidal - antagonists & inhibitors | Glucagon-Like Peptide 1 - agonists | Interleukin-1beta - metabolism | Interleukin 1 Receptor Antagonist Protein - metabolism | Purines - antagonists & inhibitors | Linagliptin | Interleukin 1 Receptor Antagonist Protein - pharmacology | Sitagliptin Phosphate | Insulin Secretion | Interleukin-1beta - antagonists & inhibitors | Recombinant Proteins - metabolism | Cell Survival - drug effects | Recombinant Proteins - antagonists & inhibitors | Cytokines - metabolism | Glucagon-Like Peptide 1 - metabolism | Purines - pharmacology | Tissue Culture Techniques | Dipeptidyl-Peptidase IV Inhibitors - chemistry | Glucagon-Like Peptide 1 - chemistry | Antioxidants - pharmacology | Recombinant Proteins - pharmacology | Insulin-Secreting Cells - immunology | Triazoles - pharmacology | Insulin - metabolism | Insulin-Secreting Cells - drug effects | Drug Inverse Agonism | Protein Stability - drug effects | Pyrazines - pharmacology | Quinazolines - pharmacology | Quinazolines - antagonists & inhibitors | Index Medicus | Abridged Index Medicus
Journal Article
Oncogene, ISSN 1476-5594, 09/2014, Volume 34, Issue 28, pp. 3700 - 3710
Androgen receptor splicing variants (ARVs) that lack the ligand-binding domain (LBD) are associated with the development of castration-resistant prostate... 
Biochemistry & Molecular Biology | Oncology | Genetics & Heredity | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Nitriles - pharmacology | Humans | Pyrazines - administration & dosage | Receptors, Androgen - metabolism | Male | NF-kappa B - metabolism | Antineoplastic Agents - administration & dosage | Prostatic Neoplasms, Castration-Resistant - genetics | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Tosyl Compounds - pharmacology | Nitriles - administration & dosage | Antineoplastic Agents - pharmacology | Boronic Acids - administration & dosage | NF-kappa B - antagonists & inhibitors | Bortezomib | Tosyl Compounds - administration & dosage | Androgen Antagonists - pharmacology | Prostatic Neoplasms, Castration-Resistant - drug therapy | Prostatic Neoplasms, Castration-Resistant - metabolism | Xenograft Model Antitumor Assays | Receptors, Androgen - genetics | Anilides - administration & dosage | Signal Transduction - drug effects | Anilides - pharmacology | Cell Line, Tumor | Androgen Antagonists - administration & dosage | Pyrazines - pharmacology | Boronic Acids - pharmacology | Androgens | Drug therapy | Gene expression | Neurons | Prostate cancer | NF-κB protein | Castration | Splicing | Xenografts | Tumors | Index Medicus
Journal Article
Journal Article
Leukemia, ISSN 0887-6924, 10/2017, Volume 31, Issue 10, pp. 2075 - 2084
Although the BTK inhibitor ibrutinib has transformed the management of patients with chronic lymphocytic leukemia (CLL), it does not induce substantial... 
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Peptide Fragments | Pyrazoles - therapeutic use | Proto-Oncogene Proteins c-bcl-2 - physiology | Apoptosis - drug effects | Humans | Neoplasm Proteins - physiology | Pyrazines - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - agonists | Neoplasm Proteins - antagonists & inhibitors | Pyrazines - therapeutic use | Molecular Targeted Therapy | Benzamides - administration & dosage | Benzamides - therapeutic use | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Sulfonamides - agonists | Benzamides - pharmacology | Proto-Oncogene Proteins | Pyrazoles - pharmacology | Pyrimidines - administration & dosage | Bcl-2-Like Protein 11 - genetics | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Clinical Trials as Topic | Mitochondria - drug effects | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Bcl-2-Like Protein 11 - biosynthesis | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Pyrazoles - administration & dosage | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Agammaglobulinaemia Tyrosine Kinase | Protein Kinase Inhibitors - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Pyrazines - pharmacology | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | Drug Screening Assays, Antitumor | Protein-Tyrosine Kinases - antagonists & inhibitors | Enzymes | Chronic lymphocytic leukemia | Care and treatment | Development and progression | Genetic aspects | Regulation | Drug resistance | Health aspects | Killing | Tyrosine | Drugs | Medical research | Chronic lymphatic leukemia | Bcl-2 protein | Leukemia | Clinical trials | Priming | Lymphatic leukemia | Patients | Bruton's tyrosine kinase | Mitochondria | Inhibitors | Cell death | Sensitivity enhancement | Inhibition | Pretreatment | Protein-tyrosine kinase | BIM protein | Apoptosis | Index Medicus | ibrutinib | BCL-2 | mitochondrial priming | acalabrutinib (ACP-196) | BTK | venetoclax | BH3 profiling
Journal Article